<DOC>
	<DOC>NCT00666185</DOC>
	<brief_summary>To determine the efficacy and safety of IV Micafungin versus IV Fluconazole in the treatment of patients with Esophageal Candidiasis</brief_summary>
	<brief_title>Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis, Oral</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Diagnosis of esophageal candidiasis confirmed by endoscopy Negative pregnancy test in females of childbearing potential Pregnant or nursing Evidence of liver disease Presence of another active opportunistic fungal infection and/or receiving acute systemic therapy for an opportunistic fungal infection Concomitant esophagitis caused by herpes simplex virus or cytomegalovirus Receipt of an oral or topical antifungal agent within 48 hours or a systemic agent within 72 hours of first dose of study drug Nonresponsive to therapy in any prior systemic antifungal clinical trail History of &gt; 2 episodes of esophageal candidiasis requiring systemic antifungal therapy History of anaphylaxis attributed to azole compounds or echinocandin class of antifungals</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Micafungin</keyword>
	<keyword>Esophageal Candidiasis</keyword>
	<keyword>Fluconazole</keyword>
</DOC>